Diagnostics
Half-lives measured in minutes. A production network built to deliver to patients just-in-time.
Ionetix's FDA-approved PET production sites make nitrogen-13 (N-13) ammonia on site, using Ionetix cyclotrons minutes from the scanner. N-13 has approximately a ten-minute half-life and a usable window of roughly 45 minutes. The only way to get an N-13 ammonia dose into a patient is to make it where the patient is.
Most of the Ionetix PET production sites utilize the bespoke ION-12SC cyclotron. The ION-12SC offers a compact design that provides a simple, reliable, and productive solution. This opens the door for the opportunity to provide superior imaging simply and affordably.
The ION-12SC Cyclotron is a 12 MeV, superconducting cyclotron that accelerates protons to produce megabecquerel levels of positron emitting isotopes to be used to produce radiopharmaceuticals for PET imaging. Designed for small spaces, our total system has a small footprint providing the flexibility to install it in reduced spaces.
Ionetix has produced F-18 on its ION-12SC cyclotron and is exploring partnership opportunities for commercial launch.
Additionally, Ionetix produces gallium-68 gozetotide on a generator.
Approved
- Half-life
- ~68 min
- Production
- Generator
Ga-68 PSMA-11
Gallium Ga-68 gozetotide for PSMA PET imaging. First ANDA approval granted to a commercial drug manufacturer, May 2026.
Partnering
- Half-life
- ~110 min
- Production
- Cyclotron
F-18
Produced on the ION-12SC cyclotron, available to partners holding a filing.
Shipping
- Half-life
- ~10 min
- Production
- Cyclotron
N-13 Ammonia
Cardiac PET tracer, produced on a cyclotron at every site in the network, under Ionetix's own ANDA.
FAQ
Ionetix manufactures N-13 ammonia for cardiac PET and gallium Ga 68 gozetotide (PSMA-11) for prostate cancer imaging, and has produced F-18 on its ION-12SC cyclotron.
Many PET isotopes decay too quickly to travel far. N-13 has a half-life of about 10 minutes and a usable window of roughly 45 minutes, so it must be made where the patient is.
Ionetix operates a network of nine FDA-approved PET production sites across the United States.
Yes. Ionetix offers CMO/CDMO services, covering manufacturing, quality and regulatory support, including submission work.
Contact